Ethos Technologies Inc. - Class A Common Stock (NQ:LIFE)

36.13 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ethos Technologies Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >

7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023 ↗

June 28, 2023

Bard AI has consistently outperformed, and it has identified seven growth stocks that it believes will deliver triple-digit returns.

Via InvestorPlace

The Latest Analyst Ratings for aTyr Pharma ↗

May 23, 2023

Via Benzinga

aTyr Pharma: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

3 Stocks and Cryptos With the Highest Potential Returns ↗

May 07, 2023

If you're only worried about upside, these stocks and cryptos have some of the highest possible returns in the market.

Via InvestorPlace

7 Hot Growth Stocks Poised to Triple in 2023 ↗

May 05, 2023

These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher.

Via InvestorPlace

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗

March 11, 2023

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...

Via Benzinga

Where aTyr Pharma Stands With Analysts ↗

March 10, 2023

Via Benzinga

aTyr Pharma's Earnings: A Preview ↗

March 08, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

February 09, 2023

We're starting off another day of trading with a look at the biggest pre-market stock movers investors need to watch for Wednesday!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 08, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 03, 2023

Via Benzinga

This Company Is Beginning A Pivotal Phase 3 EFZO-FIT™ Study. Could It Be A Much-Needed Treatment For Pulmonary Sarcoidosis? ↗

November 29, 2022

Most people may never have heard of sarcoidosis, an inflammatory disease that affects about 1.2 million people worldwide.

Via Benzinga

aTyr Pharma: Q2 Earnings Insights ↗

August 15, 2022

aTyr Pharma (NASDAQ:LIFE) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

November 18, 2022

On Friday, 64 companies achieved new lows for the year.

Via Benzinga

Beat Of Life Entertainment- A One Stop Solution For Internet Marketing

October 08, 2022

Internet marketing is the solution for business development in the digitalization era.

Via IssueWire

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary ↗

September 13, 2022

Via Benzinga

aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate ↗

September 13, 2022

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 13, 2022

Via Benzinga

NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks ↗

August 16, 2022

Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.

Via Benzinga

A Preview Of aTyr Pharma's Earnings ↗

August 12, 2022

aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement. Analysts estimate that aTyr Pharma...

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 11, 2022

Via Benzinga

Earnings Scheduled For August 15, 2022 ↗

August 15, 2022

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.

Via Benzinga

aTyr Pharma Shares Ascend As FDA Grants Fast Track Status To Lung Disease Candidate ↗

August 11, 2022

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 11, 2022

Via Benzinga

Snap to $25? Plus This Analyst Cuts Price Target On Amazon.com ↗

July 21, 2022

Keybanc cut the price target for Snap Inc. (NYSE: SNAP) from $27 to $25. Snap is scheduled to release its second-quarter results after the closing bell on Thursday. Snap shares rose 0.3% to $15.55 in...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 13, 2022

Gainers

Via Benzinga

$1.4 Million Bet On This Healthcare Stock? 4 Penny Stocks Insiders are Buying ↗

July 07, 2022

U.S. stock futures traded higher this morning on Thursday after closing slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗

May 16, 2022

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...

Via Benzinga

Earnings Outlook For aTyr Pharma ↗

May 06, 2022

aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that aTyr Pharma will...

Via Benzinga

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.